Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 TrialElias K. Mai,Hans Salwender,Michael Hundemer,Uta Bertsch, Ema Pozek,Axel Benner,Roland Fenk,Britta Besemer,Christine Hanoun,Roland Schroers,Ivana von Metzler,Mathias Hänel,Christoph Mann,Lisa Leypoldt,Bernhard Heilmeier,Stefanie Huhn, Sabine Vogel,Christof Scheid,Igor Wolfgang Blau,Steffen Luntz,Niels Weinhold,Tobias A.W. Holderried,Karolin Trautmann-Grill,Deniz Gezer, Maika Klaiber-Hakimi, Martin Mueller,Evgenii Shumilov,Wolfgang Knauf, Christian Sebastian Michel,Thomas Geer,Hendrik Riesenberg,Christoph Lutz,Marc S. Raab,Martin Hoffmann,Katja C. Weisel,Hartmut GoldschmidtBlood(2024)Cited 0|Views3AI Read ScienceMust-Reading TreeExampleGenerate MRT to find the research sequence of this paperChat PaperSummary is being generated by the instructions you defined